<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02046434</url>
  </required_header>
  <id_info>
    <org_study_id>13-2808</org_study_id>
    <nct_id>NCT02046434</nct_id>
  </id_info>
  <brief_title>Phenylbutyrate Response as a Biomarker for Alpha-synuclein Clearance From the Brain</brief_title>
  <official_title>Phenylbutyrate Response As a Biomarker for Alpha-Synuclein Clearance From Brain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase I clinical trial of the FDA approved drug Glycerol Phenylbutyrate to see if&#xD;
      phenylbutyrate can increase the removal of alpha-synuclein from the brain into the&#xD;
      bloodstream. Alpha-synuclein forms abnormal protein deposits in dopamine neurons and is&#xD;
      believed to cause the death of brain cells, leading to Parkinson's Disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase I clinical trial of phenylbutyrate in 20 Parkinson patients and 20 age- and&#xD;
      sex-matched normal control subjects to see if phenylbutyrate can increase the removal of&#xD;
      alpha-synuclein from the brain into the bloodstream. All subjects will receive 20 grams/day&#xD;
      of phenylbutyrate in the liquid form phenylbutyrate-triglyceride taken as one teaspoonful&#xD;
      three times per day with meals. Blood will be drawn on two days prior to starting&#xD;
      phenylbutyrate to measure alpha-synuclein concentrations. Phenylbutyrate-triglyceride will&#xD;
      then be started and the change in plasma alpha-synuclein will be measured on day 1, 7, 14,&#xD;
      and 21 days while taking phenylbutyrate. After 21 days, the drug will be stopped and a final&#xD;
      blood sample will be measured at 28 days to see if plasma alpha-synuclein has fallen to its&#xD;
      pre-phenylbutyrate level. No effects on Parkinson symptoms are expected during this short&#xD;
      trial. Please note that although taking any type of Parkinson's drugs for symptomatic&#xD;
      treatment disqualifies you, if you and your neurologist are willing and able to have you off&#xD;
      Parkinson medication for six weeks before and during the trial, you may be eligible to&#xD;
      participate.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 2014</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Levels of alpha-synuclein in blood plasma</measure>
    <time_frame>1 month</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>Parkinson's Diesase</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participant will take Glycerol Phenylbutyrate, participant has Parkinson's Disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participant does not have Parkinson's Disease, Participant will be taking glycerol phenylbutyrate</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glycerol Phenylbutyrate</intervention_name>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Parkinson's Diesase</arm_group_label>
    <other_name>Ravicti</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Idiopathic Parkinson's disease with mild symptoms;&#xD;
&#xD;
          -  May be on treatment with dopamine agonists provided that the treating neurologist&#xD;
             agrees:&#xD;
&#xD;
               1. that the drugs can be stopped for at least three weeks prior to participating in&#xD;
                  the phenylbutyrate study, and&#xD;
&#xD;
               2. for the 4-week duration of the study.&#xD;
&#xD;
          -  Age and sex matched normal control subjects from spouses and the general population;&#xD;
&#xD;
          -  In good general health;&#xD;
&#xD;
          -  Controlled hypertension, or&#xD;
&#xD;
          -  Controlled hypercholesterolemia with medication.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant women;&#xD;
&#xD;
          -  Current treatment with:&#xD;
&#xD;
               1. L-3,4-dihydroxyphenylalanine (L-DOPA);&#xD;
&#xD;
               2. monoamine oxidase (MAO) inhibitors,&#xD;
&#xD;
               3. catechol-O-methyl transferase (COMT) inhibitors;&#xD;
&#xD;
               4. histone deacetylase (HDAC) inhibitors;&#xD;
&#xD;
               5. prednisone or other corticosteroids, or&#xD;
&#xD;
               6. probenecid.&#xD;
&#xD;
          -  Severe cardiopulmonary disease such as:&#xD;
&#xD;
               1. congestive heart failure, or&#xD;
&#xD;
               2. emphysema requiring supplemental oxygen;&#xD;
&#xD;
          -  Renal disease with serum creatinine greater than 2.5;&#xD;
&#xD;
          -  History of:&#xD;
&#xD;
               1. depression in the prior year;&#xD;
&#xD;
               2. epilepsy;&#xD;
&#xD;
               3. stroke;&#xD;
&#xD;
               4. prior brain surgery;&#xD;
&#xD;
               5. dementia, or&#xD;
&#xD;
               6. psychosis.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Curt R Freed, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Colorado Denver Anschutz Medical Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>January 23, 2014</study_first_submitted>
  <study_first_submitted_qc>January 23, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2014</study_first_posted>
  <last_update_submitted>May 26, 2021</last_update_submitted>
  <last_update_submitted_qc>May 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>4-phenylbutyric acid</mesh_term>
    <mesh_term>Glycerol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

